TY - JOUR
T1 - A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials
AU - the Dominantly Inherited Alzheimer Network
AU - Xiong, Chengjie
AU - Luo, Jingqin
AU - Agboola, Folasade
AU - Li, Yan
AU - Albert, Marilyn
AU - Johnson, Sterling C.
AU - Koscik, Rebecca L.
AU - Masters, Colin L.
AU - Soldan, Anja
AU - Villemagne, Victor L.
AU - Li, Qiao Xin
AU - McDade, Eric M.
AU - Fagan, Anne M.
AU - Massoumzadeh, Parinaz
AU - Benzinger, Tammie
AU - Hassenstab, Jason
AU - Bateman, Randall J.
AU - Morris, John C.
N1 - Funding Information:
This study was supported by National Institute on Aging (NIA) grant R01 AG053550 (Dr. Xiong) and NIA grant P50 AG005681, P01AG026276, and P01 AG0399131 (Dr. Morris), UF1AG032438 (Dr. Bateman), U19-AGO33655 and R01 AG059869 (Albert), R01-AG027161 and R01 AG021155 (Johnson), P50AG033514 (Asthana), and Australian Commonwealth Scientific Industrial Research Organization (Masters).The AIBL study (www.AIBL.csiro.au) was supported by the Alzheimer's Association (US), the Alzheimer's Drug Discovery Foundation, an Anonymous foundation, the Science and Industry Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government's Operational Infrastructure Support program, the McCusker Alzheimer's Research Foundation, the National Health and Medical Research Council, and the Yulgilbar Foundation, plus numerous commercial interactions that supported data collection and analysis. Image processing was supported in part by the Neuroimaging Informatics and Analysis Center (1P30NS098577) and R01 EB009352. Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network (DIAN, UF1AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This article has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. The authors acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study.
Funding Information:
Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network ( DIAN , UF1AG032438 ) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development , AMED , and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This article has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. The authors acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study.
Funding Information:
This study was supported by National Institute on Aging (NIA) grant R01 AG053550 (Dr. Xiong) and NIA grant P50 AG005681 , P01AG026276 , and P01 AG0399131 (Dr. Morris), UF1AG032438 (Dr. Bateman), U19-AGO33655 and R01 AG059869 (Albert), R01-AG027161 and R01 AG021155 (Johnson), P50AG033514 (Asthana), and Australian Commonwealth Scientific Industrial Research Organization (Masters).The AIBL study ( www.AIBL.csiro.au ) was supported by the Alzheimer's Association (US), the Alzheimer's Drug Discovery Foundation , an Anonymous foundation , the Science and Industry Endowment Fund , the Dementia Collaborative Research Centres , the Victorian Government's Operational Infrastructure Support program, the McCusker Alzheimer's Research Foundation , the National Health and Medical Research Council , and the Yulgilbar Foundation , plus numerous commercial interactions that supported data collection and analysis. Image processing was supported in part by the Neuroimaging Informatics and Analysis Center ( 1P30NS098577 ) and R01 EB009352 .
Publisher Copyright:
© 2019 the Alzheimer's Association
PY - 2019/11
Y1 - 2019/11
N2 - Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.
AB - Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.
KW - Alzheimer disease
KW - Amyloid imaging with positron emission tomography (PET) using the [C] benzothiazole tracer
KW - Biomarkers
KW - Cerebrospinal fluid (CSF)
KW - Magnetic resonance imaging (MRI) volumetrics
KW - Pittsburgh Compound-B (PIB)
KW - Preclinical stages
KW - Prevention trials
UR - http://www.scopus.com/inward/record.url?scp=85071846017&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2019.06.4955
DO - 10.1016/j.jalz.2019.06.4955
M3 - Article
C2 - 31506247
AN - SCOPUS:85071846017
SN - 1552-5260
VL - 15
SP - 1448
EP - 1457
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 11
ER -